KR100671392B1 - 항균제로서의 화합물의 신규한 용도 - Google Patents

항균제로서의 화합물의 신규한 용도 Download PDF

Info

Publication number
KR100671392B1
KR100671392B1 KR1020017015407A KR20017015407A KR100671392B1 KR 100671392 B1 KR100671392 B1 KR 100671392B1 KR 1020017015407 A KR1020017015407 A KR 1020017015407A KR 20017015407 A KR20017015407 A KR 20017015407A KR 100671392 B1 KR100671392 B1 KR 100671392B1
Authority
KR
South Korea
Prior art keywords
formula
delete delete
wells
helicobacter pylori
releasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017015407A
Other languages
English (en)
Korean (ko)
Other versions
KR20020015334A (ko
Inventor
아르네 이이크
조한 라우드
Original Assignee
니콕스 에스. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902027A external-priority patent/SE9902027D0/xx
Priority claimed from SE9904704A external-priority patent/SE9904704D0/xx
Application filed by 니콕스 에스. 에이. filed Critical 니콕스 에스. 에이.
Publication of KR20020015334A publication Critical patent/KR20020015334A/ko
Application granted granted Critical
Publication of KR100671392B1 publication Critical patent/KR100671392B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020017015407A 1999-06-01 2000-05-25 항균제로서의 화합물의 신규한 용도 Expired - Fee Related KR100671392B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9902027A SE9902027D0 (sv) 1999-06-01 1999-06-01 New use
SE9902027-3 1999-06-01
SE9904704A SE9904704D0 (sv) 1999-12-21 1999-12-21 New use
SE9904704-5 1999-12-21

Publications (2)

Publication Number Publication Date
KR20020015334A KR20020015334A (ko) 2002-02-27
KR100671392B1 true KR100671392B1 (ko) 2007-01-22

Family

ID=26663588

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017015407A Expired - Fee Related KR100671392B1 (ko) 1999-06-01 2000-05-25 항균제로서의 화합물의 신규한 용도

Country Status (27)

Country Link
US (2) US6593339B1 (https=)
EP (1) EP1196155B1 (https=)
JP (1) JP4818516B2 (https=)
KR (1) KR100671392B1 (https=)
CN (1) CN1165298C (https=)
AR (1) AR024159A1 (https=)
AT (1) ATE272396T1 (https=)
AU (1) AU780678B2 (https=)
BG (1) BG106158A (https=)
BR (1) BR0011116A (https=)
CA (1) CA2373653C (https=)
CZ (1) CZ20014289A3 (https=)
DE (1) DE60012745T2 (https=)
EE (1) EE200100647A (https=)
HK (1) HK1045814B (https=)
HU (1) HUP0201502A3 (https=)
IL (1) IL146407A0 (https=)
IS (1) IS6185A (https=)
MX (1) MXPA01012295A (https=)
NO (1) NO20015855L (https=)
NZ (1) NZ515317A (https=)
PL (1) PL352744A1 (https=)
RU (1) RU2252032C2 (https=)
SK (1) SK17392001A3 (https=)
TR (1) TR200103474T2 (https=)
TW (1) TWI243672B (https=)
WO (1) WO2000072838A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
CA2393724A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド，インク． 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
EP2260837A1 (en) 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
WO2003103602A2 (en) * 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003279622A1 (en) 2002-06-28 2004-01-19 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
AU2003261281A1 (en) 2002-07-29 2004-02-16 Nicox S.A. Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
WO2004012659A2 (en) 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
AU2003283096A1 (en) * 2002-11-05 2004-06-07 Merck Frosst Canada And Co. Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) * 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
SE0301880D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Uk Ltd New drug delivery composition
JP5137400B2 (ja) * 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
US20050054714A1 (en) * 2003-07-17 2005-03-10 Benito Munoz Nitric oxide releasing drugs for Alzheimer's disease
JP4917889B2 (ja) 2003-09-25 2012-04-18 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を処置するための組成物及びその使用方法
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
ATE485033T1 (de) * 2005-07-26 2010-11-15 Nicox Sa Pharmazeutische formulierung von nitrooxy- derivaten von nsar
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE
CN103298826A (zh) 2010-11-15 2013-09-11 特拉维夫大学拉莫特有限公司 用于治疗淀粉样纤维形成相关疾病的二肽类似物
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
CN104815330A (zh) * 2015-05-22 2015-08-05 杜林� 乙酸类非甾体抗炎药的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
IL98680A0 (en) 1991-06-30 1992-07-15 Yeda Res & Dev Hydroxamate derivatives and pharmaceutical compositions containing them
IT1256345B (it) * 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
DE69412109T2 (de) * 1993-10-06 1999-01-21 Nicox S.A., Paris Salzetersaüreester mit entzündungshemmender und/oder schmerzlindernder wirkung und verfahren zu deren herstellung
AU7972294A (en) * 1993-10-07 1995-05-01 Entremed, Inc Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
SI0759899T1 (en) 1994-05-10 1999-12-31 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US5785689A (en) 1996-07-18 1998-07-28 Act Medical, Inc. Endoscopic catheter sheath position control
WO1998022117A1 (en) * 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
US6207855B1 (en) 1998-06-23 2001-03-27 Duke University Medical Center Stable no-delivering compounds
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents

Also Published As

Publication number Publication date
DE60012745T2 (de) 2005-09-15
HK1045814A1 (en) 2002-12-13
NO20015855D0 (no) 2001-11-30
AR024159A1 (es) 2002-09-04
RU2252032C2 (ru) 2005-05-20
MXPA01012295A (es) 2002-07-30
US20040048917A1 (en) 2004-03-11
KR20020015334A (ko) 2002-02-27
CA2373653A1 (en) 2000-12-07
CZ20014289A3 (cs) 2002-05-15
NO20015855L (no) 2002-01-30
IS6185A (is) 2001-11-29
US6593339B1 (en) 2003-07-15
JP2003500442A (ja) 2003-01-07
AU5262300A (en) 2000-12-18
NZ515317A (en) 2004-05-28
IL146407A0 (en) 2002-07-25
CA2373653C (en) 2011-03-15
WO2000072838A1 (en) 2000-12-07
DE60012745D1 (de) 2004-09-09
CN1354658A (zh) 2002-06-19
HK1045814B (en) 2005-04-01
TWI243672B (en) 2005-11-21
AU780678B2 (en) 2005-04-07
CN1165298C (zh) 2004-09-08
PL352744A1 (en) 2003-09-08
EP1196155A1 (en) 2002-04-17
SK17392001A3 (sk) 2002-07-02
HUP0201502A3 (en) 2003-03-28
HUP0201502A2 (en) 2002-08-28
EE200100647A (et) 2003-02-17
JP4818516B2 (ja) 2011-11-16
EP1196155B1 (en) 2004-08-04
BG106158A (en) 2002-06-28
BR0011116A (pt) 2002-02-19
TR200103474T2 (tr) 2002-04-22
ATE272396T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
KR100671392B1 (ko) 항균제로서의 화합물의 신규한 용도
RU2001135826A (ru) Новое применение соединений в качестве антибактериальных средств
AU726859B2 (en) Administration regimen of H+, K+-ATPase inhibitors
JP2003500442A5 (https=)
NO20055892L (no) Karboksylsyrederivater
AU2019312592B2 (en) Bismuth-thiol compositions and methods for treating wounds
EP0865788A1 (en) Specific cyclooxygenase 2 inhibitor and anti-inflammatory agent
JP2004508295A (ja) 抗菌剤として有用な新規な化合物
CA2005980A1 (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
JP2003512464A (ja) 新規インドール化合物
US6423707B1 (en) Nitroimidazole ester analogues and therapeutic applications
RU2336872C2 (ru) Аннелированные пиррольные соединения как ингибиторы протонового насоса для лечения язвы
KR100483092B1 (ko) H+,k+-atp아제억제제의투여방법
EP1057487A1 (en) Antimicrobial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith
WO2005074898A2 (en) Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori
ZA200109497B (en) New use of compounds as antibacterial agents.
JPH0977766A (ja) ４−アミノ−５−ピリミジンカルボン酸誘導体を有効 成分とする抗菌剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20091230

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110113

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110113

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000